Continuing low-dose aspirin during minimally invasive lumbar fusion surgery was not associated with increased surgical complications or blood loss, according to a study published Nov. 15 in Spine.
Researchers retrospectively examined 455 adults who underwent minimally invasive anterior-to-psoas lumbar fusion with supplemental posterior percutaneous fixation at a single academic medical center between 2014 and 2020. Of those patients, 134 continued aspirin around the time of surgery, while 321 discontinued it beforehand.
After matching 86 pairs of patients based on demographic and clinical factors, researchers found no statistically significant differences in operative time, estimated blood loss, postoperative day-1 hemoglobin levels or hospital length of stay.
Transfusion rates were 18.6% among patients who continued aspirin and 15.1% among those who discontinued it, a difference that was not statistically significant. Retroperitoneal hematoma rates were identical at 1.2% in both groups.
A separate analysis of 15 matched pairs found no outcome advantage among patients who stopped aspirin at least seven days before surgery compared with those who continued treatment.
The researchers concluded that continuing low-dose aspirin in appropriately selected patients undergoing this procedure was not associated with increased surgical morbidity or postoperative complications, supporting individualized, approach-specific decisions about perioperative antiplatelet management.
